Key Points
- Vera Therapeutics CEO Marshall Fordyce sold 18,500 shares on May 12 at an average price of $36.74, totaling about $679,690. The sale was made under a pre-arranged Rule 10b5-1 plan, and he now holds 216,744 shares.
- The CEO has been actively trimming his stake, with additional sales in April and February worth about $1.01 million and $710,512, respectively. These transactions have reduced his position by 7.86% in the latest trade alone.
- Vera Therapeutics recently reported weaker-than-expected quarterly results, posting a loss of $1.69 per share versus the $1.33 loss analysts expected. Despite that, Wall Street remains generally upbeat, with a Moderate Buy consensus and a $79.60 average price target.
Vera Therapeutics, Inc. (NASDAQ:VERA - Get Free Report) CEO Marshall Fordyce sold 18,500 shares of the company's stock in a transaction on Tuesday, May 12th. The stock was sold at an average price of $36.74, for a total transaction of $679,690.00. Following the transaction, the chief executive officer owned 216,744 shares of the company's stock, valued at approximately $7,963,174.56. The trade was a 7.86% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Marshall Fordyce also recently made the following trade(s):
- On Tuesday, April 14th, Marshall Fordyce sold 22,951 shares of Vera Therapeutics stock. The stock was sold at an average price of $44.05, for a total transaction of $1,010,991.55.
- On Monday, February 23rd, Marshall Fordyce sold 16,925 shares of Vera Therapeutics stock. The stock was sold at an average price of $41.98, for a total transaction of $710,511.50.
Vera Therapeutics Stock Up 6.7%
Shares of Vera Therapeutics stock opened at $39.15 on Thursday. The company has a market cap of $2.79 billion, a P/E ratio of -7.07 and a beta of 0.96. The company has a debt-to-equity ratio of 0.15, a quick ratio of 13.64 and a current ratio of 13.64. Vera Therapeutics, Inc. has a one year low of $18.76 and a one year high of $56.05. The firm has a fifty day moving average of $39.63 and a two-hundred day moving average of $40.56.
Vera Therapeutics (NASDAQ:VERA - Get Free Report) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($1.69) EPS for the quarter, missing analysts' consensus estimates of ($1.33) by ($0.36). During the same period in the prior year, the firm posted ($0.81) EPS. On average, analysts forecast that Vera Therapeutics, Inc. will post -5.74 earnings per share for the current year.
Hedge Funds Weigh In On Vera Therapeutics
A number of institutional investors and hedge funds have recently made changes to their positions in VERA. GAMMA Investing LLC grew its stake in shares of Vera Therapeutics by 50.5% during the 4th quarter. GAMMA Investing LLC now owns 703 shares of the company's stock worth $36,000 after purchasing an additional 236 shares during the period. Los Angeles Capital Management LLC acquired a new position in shares of Vera Therapeutics during the 4th quarter worth $46,000. Quantbot Technologies LP acquired a new position in shares of Vera Therapeutics during the 2nd quarter worth $51,000. Aster Capital Management DIFC Ltd acquired a new position in shares of Vera Therapeutics during the 4th quarter worth $71,000. Finally, Tower Research Capital LLC TRC grew its stake in shares of Vera Therapeutics by 192.9% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,186 shares of the company's stock worth $99,000 after purchasing an additional 2,757 shares during the period. 99.21% of the stock is owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
A number of brokerages have commented on VERA. Weiss Ratings restated a "sell (d-)" rating on shares of Vera Therapeutics in a research report on Monday, April 20th. HC Wainwright upped their price objective on shares of Vera Therapeutics from $90.00 to $110.00 and gave the stock a "buy" rating in a research report on Monday, March 2nd. Finally, Wolfe Research upgraded shares of Vera Therapeutics from a "peer perform" rating to an "outperform" rating and set a $88.00 price objective for the company in a research report on Wednesday, March 11th. Ten equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Vera Therapeutics has a consensus rating of "Moderate Buy" and a consensus target price of $79.60.
Check Out Our Latest Report on VERA
About Vera Therapeutics
(
Get Free Report)
Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body's own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.
Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
